Mutations in the three RAS genes emerge in approximately 30% of all human tumors and K-Ras is the most frequently mutated variant in carcinomas, with approximately 90% in ductal pancreatic adenocarcinoma (PDAC), 50% in colon carcinoma and 30% in non-small cell lung cancer (NSCLC). This evidence concerns the gene KRAS and non-small cell lung carcinoma.